Teva Pharma (NYSE: TEVA) reported Q3 EPS of $0.78, $0.10 better than the analyst estimate of $0.68. Revenue for the quarter came in at $4.48 billion versus the consensus estimate of $4.36 billion.

GUIDANCE:

Teva Pharma sees FY2025 EPS of $2.55-$2.65, versus the consensus of $2.56. Teva Pharma sees FY2025 revenue of $16.8-17 billion, versus the consensus of $16.8 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.